Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates

Neuropharmacology

Volumn 52, Issue 2, 2007, Pages 515-526

  Smith, C P S ^a   Oh, J D ^b   Bibbiani, F ^a   Collins, M A ^b   Avila, I ^a   Chase, T N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b CENTRAL MICHIGAN UNIVERSITY   (United States)

Author keywords

6 Hydroxydopamine lesion; Motor response alteration; Parkinson's disease; PKC isoforms; Tamoxifen

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIESTROGEN; CARBIDOPA PLUS LEVODOPA; ISOPROTEIN; LEVODOPA; OXIDOPAMINE; PROTEIN KINASE C; PROTEIN KINASE C EPSILON; PROTEIN KINASE C LAMBDA; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE INCREASE; DRUG EFFECT; DRUG RESPONSE; DYSKINESIA; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME POLYMORPHISM; IMMUNOREACTIVITY; MALE; MONKEY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; HAPLORHINI; LEVODOPA; MALE; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS;

EID: 33846333455     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.08.018     Document Type: Article

References (58)

1. Araki T., Tanji H., Kato H., Mizugaki M., and Itoyama Y. Alterations of second messenger systems in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle. European Journal of Pharmaceutical Sciences 8 (1999) 261-267
2. Bascunan-Castillo E.C., Erickson E.P., Howison C.M., Hunter R.J., Heidenreich R.H., Hicks C., Trouard T.P., and Gillies R.J. Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. Journal of Applied Genetics 45 (2004) 461-467
3. Blecheva M.M., Clark A.L., Haas P.D., Serna J.S., Hahn J.W., Kiss A., and Coscia C.J. μ and κ opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. Journal of Biological Chemistry 280 (2005) 27662-27669
4. Bibbiani F., and Chase T.N. 5HT2A antagonist improves levodopa-induced dyskinesias in MPTP lesioned cynomolgus monkeys. Neurology 56 (2001) 376-377
5. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., and Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. Journal of Pharmacology and Experimental Therapeutics 290 (1999) 1034-1040
6. Borlongan C.V., and Sanberg P.R. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. Journal of Neuroscience 15 (1995) 5372-5378
7. Calon F., Tahar A.H., Blanchet P.J., Morissette M., Grondin R., Goulet M., Doucet J.P., Robertson G.S., Nestler E., Di Paolo T., and Bedard P. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends in Neurosciences 23 (2000) S92-S100
8. Casabona G. Intracellular signal modulation: a pivotal role for protein kinase C. Progress in Neuropsychopharmacology and Biological Psychiatry 21 (1997) 407-425
9. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., Abrahan L., and Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology 26 (2004) 955-969
10. Chase T.N. Levodopa therapy: consequences of the non-physiological replacement of dopamine. Neurology 50 (1998) S17-S25
11. Chase T.N., and Oh J.D. Striatal dopamine and glutamate mediated dysregulation in experimental parkinsonism. Trends in Neurosciences 23 (2000) S86-S91
12. Chase T.N., Oh J.D., and Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Journal of Neurology 247 (2000) 36-42
13. Chaurasia C.S., Chen C.E., Rubin J., and Dewey S.L. Effects of tamoxifen on striatal dopamine and 5-hydroxytryptamine release in freely moving male rats: an in-vivo microdialysis investigation. Journal of Pharmacy and Pharmacology 50 (1998) 1377-1385
14. Chen L., Togasaki D.M., Langston J.W., DiMonte D.A., and Quik M. Enhanced striatal opioid receptor mediated G-protein activation in L-dopa-treated dyskinetic monkeys. Neuroscience 132 (2005) 409-420
15. Cordey M., and Pike C.J. Conventional protein kinase C isoforms mediate neuroprotection induced by phorbol ester and estrogen. Journal of Neurochemistry 96 (2006) 204-217
16. D'Astous M., Morissette M., Callier S., and Di Paolo T. Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol. Journal of Neuroscience Research 80 (2005) 138-144
17. Dluzen D.E. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. Journal of Neurocytology 29 (2000) 387-399
18. Dluzen D.E., Gao X., Story G.M., Anderson L.I., Kucera J., and Walro J.M. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice. Experimental Neurology 170 (2001) 121-128
19. Dluzen D.E., and Mickley K.R. Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system. Pharmacology Biochemistry and Behavior 80 (2005) 27-33
20. Eberling J.L., Wu C., Tong-Turnbeaugh R., and Jagust W.J. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 21 (2004) 364-371
21. Fang L., Wu J., Lin Q., and Willis W.D. Protein kinases regulate the phosphorlyation of the GluR1 subunit of AMPA receptors of spinal cord in rats following noxious stimulation. Brain Research 118 (2003) 160-165
22. Gorski J.A., Gomez L.L., Scott J.D., and Dell'Acqua M.L. Association of an A-kinase-anchoring protein signaling scaffold with cadherin adhesion molecules in neurons and epithelial cells. Molecular Biology of the Cell 16 (2005) 3574-3590
23. Henry B., Crossman A.R., and Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental Neurology 155 (1999) 204-220
24. Hoffmann J., and Sommer A. Steroid hormone receptors as targets for the therapy of breast and prostate cancer - recent advances, mechanisms of resistance, and new approaches. Journal of Steroid Biochemistry and Molecular Biology 93 (2005) 191-200
25. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51 (1998) S2-S9
26. Hourez R., Azdad K., Vanwalleghem G., Roussel C., Gall D., and Schiffman S.N. Activation of protein kinase C and inositol 1,4,5-triphosphate receptors antagonistically modulate voltage-gated sodium channels in striatal neurons. Brain Research 1059 (2005) 189-196
27. 2+ movement in Chinese hamster ovary (CHO-K1) cells. Archives of Toxicology 160 (2003) 160-166
28. Jenkins V., Schilling V., Fallowfield L., Howell A., and Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13 (2004) 61-66
29. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 61 (2003) S4-S11
30. Jung M.E., Watson D.G., and Simpkins J.W. Suppression of protein kinase C mediates 17b-estradiol-induced neuroprotection in an immortalized hippocampal cell line. Journal of Neurochemistry 95 (2005) 745-755
31. Kampfer S., Villunger A., Doppler W., Baier G., Grunicke H.H., and Uberall F. Transcriptional activation of c-fos by oncogenic Ha-Ras in mouse mammary epithelial cells requires the combined activities of PKC-lambda, epsilon and zeta. EMBO Journal 17 (1998) 4046-4055
32. Kang J., Yang M., Jou I., and Joe E. Identification of protein kinase C isoforms involved in interferon-gamma-induced expression of inducible nitric oxide synthase in murine BV2 microglia. Neuroscience Letters 299 (2001) 205-208
33. Kawakami R., Shinohara Y., Kato Y., Sugiyama H., Shigemoto R., and Ito I. Asymmetrical allocation of NMDA receptor epsilon 2 subunits in hippocampal circuitry. Science 300 (2003) 990-994
34. Kelly M.J., Lagrange A.H., Wagner E.J., and Ronnekleiv O.K. Rapid effects of estrogen to modulate G protein-coupled receptors via activation of protein kinase A and protein kinase C pathways. Steroids 64 (1999) 64-75
35. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., and Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54 (2000) 1589-1595
36. Lee M.Y., Heo J.S., and Han H.J. Dopamine regulates cell cycle regulatory proteins via cAMP, Ca (2+)/PKC, MAPKs, and NF-kappaB in mouse embryonic stem cells. Journal of Cellular Physiology 208 (2006) 339-406
37. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193 (1951) 265-275
38. Lu Y.C., Jiann B.P., Chang H.T., Huang J.K., Chen W.C., Su W., and Jan C.R. Effect of the anti-breast cancer drug tamoxifen on Ca(2+) movement in human osteosarcoma cells. Journal of Pharmacological and Toxicological Methods 91 (2002) 34-39
39. Marin C., Jimenez A., Bonastre M., Chase T.N., and Tolosa E. Non-NMDA receptor mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse 36 (2000) 267-274
40. Mellor H., and Parker P.J. The extended protein kinase C superfamily. Journal of Biochemistry 332 (1998) 281-292
41. Metman L.V., van den Munckhof P., Klaassen A.A.G., Blanchet P., Mouradian M.M., and Chase T.N. Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease - Reply. Neurology 51 (1998) 649-650
42. Miyawaki E., Lyons K., Pahwa R., Troster A.I., Hubble J., Smith D., Busenbark K., McGuire D., Michalek D., and Koller W.C. Motor complications of chronic levodopa therapy in Parkinson's disease. Clinical Neuropharmacology 20 (1997) 523-530
43. Muscella A., Greco S., Elia M.G., Storelli C., and Marsigliante S. Differential signaling of purinoceptors in HeLa cells through the extracellular signal-regulated kinase and protein kinase C pathways. Journal of Cellular Physiology 200 (2004) 428-439
44. Napolitano M., Picconi B., Centonze D., Bernardi G., Calabresi P., and Gulino A. L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. Neuroscience Letters 398 (2006) 211-214
45. Obata T. Activation of protein kinase C enhances 1-methyl-4-phenylpyridinium ion (MPP+)-induced hydroxyl radical generation in rat striatum. Neuroscience Letters 398 (2006) 50-52
46. Obata T., and Kubota S. Protective effects of tamoxifen on 1-methly-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neuroscience Letters 308 (2001) 87-90
47. O'Brian C.A., Liskamp R.M., Solomon D.H., and Weinstein I.B. Inhibition of protein kinase C by tamoxifen. Cancer Research 45 (1985) 2462-2465
48. Oh J.D., Russell D.S., Vaughan C.L., and Chase T.N. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Research 813 (1998) 150-159
49. Oh J.D., Geller A.I., Zhang G.R., and Chase T.N. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Research 971 (2003) 18-30
50. O'Neill K., Chen S., and Diaz Brinton R. Impact of the selective estrogen receptor modulator, tamoxifen, on neural outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Experimental Neurology 188 (2004) 268-278
51. Otani S., Ben-Ari Y., and Roisin-Lallemand M.P. Metabolic receptor stimulation coupled to weak tetanus leads to long-term potentiation and a rapid elevation of cytosolic protein kinase C activity. Brain Research 613 (1993) 1-9
52. Papa S.M., Engber T.M., Kask A.M., and Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats - relation to lesion extent and treatment duration. Brain Research 662 (1994) 69-74
53. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 51 (1998) S25-S29
54. Ravenscroft P., Chalon S., Brotchie J.M., and Crossman A.R. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exploratory Neurology 185 (2004) 36-46
55. Robertson D.W., Katzenellenbogen J.A., Long D.J., Rorke E.A., and Katzenellenbogen B.S. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. Journal of Steroid Biochemistry 16 (1982) 1-13
56. Smith C.P.S., Oh J.D., and Chase T.N. Enhanced striatal PKC lambda contributes to the development of levodopa-induced motor response alterations in hemiparkinsonian rats. Society of Neuroscience Abstracts 734.4 (2003)
57. Suen P., Wu K., Xu J.L., Lin S.Y., Levine E.S., and Black I.B. NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Molecular Brain Research 59 (1998) 215-228
58. Zeng B.Y., Pearce R.K., MacKenzie G.M., and Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA. European Journal of Neuroscience 12 (2000) 1096-1104